—
TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026
—
Leerink 2026 Global Healthcare Conference on Monday, March 9, 2026
—
Jefferies 2026 Biotech on the Beach Summit on Tuesday, March 10, 2026
—
Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March.
TD Cowen 46th Annual Health Care Conference
(Boston, MA)
— Wednesday, March 4th, Alexander Hardy, President & Chief Executive Officer and Brian Mueller, Executive Vice President, Chief Financial Officer will participate in a fireside chat at 10:30am ET and host 1×1 meetings
Leerink 2026 Global Healthcare Conference (Miami, FL)
— Monday, March 9th, Cristin Hubbard, Executive Vice President, Chief Commercial Officer and Brian Mueller, Executive Vice President, Chief Financial Officer will participate in a fireside chat at 8:00am ET and host 1×1 meetings
Jefferies 2026 Biotech on the Bay Summit (Miami, FL)
— Tuesday, March 10th, Cristin Hubbard, Executive Vice President, Chief Commercial Officer and Brian Mueller, Executive Vice President, Chief Financial Officer will host 1×1 meetings
Barclays 28th Annual Global Healthcare Conference (Miami, FL)
— Wednesday, March 11th, Cristin Hubbard, Executive Vice President, Chief Commercial Officer and Brian Mueller, Executive Vice President, Chief Financial Officer will participate in a fireside chat at 2:00pm ET and host 1×1 meetings
The fireside chats will be webcast live and can be accessed by visiting BioMarin’s website at https://investors.biomarin.com/. A webcast replay will be available through the Company’s website for a limited time following the conferences.
About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the?San Rafael, California-based company has a proven track record of innovation, with multiple commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Contacts:
Investors
Media
Traci McCarty
Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical
Inc.
(415) 455-7558 (650) 374-2803
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-four-upcoming-investor-conferences-in-march-302695288.html
SOURCE BioMarin Pharmaceutical Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=SF94164&Transmission_Id=202602240900PR_NEWS_USPR_____SF94164&DateId=20260224
COMTEX_474143387/1005/2026-02-24T09:01:22